Second Primary Malignancies in Multiple Myeloma: an Overview and IMWG Consensus

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2017 May 26

PMID 28541409

Citations 8

Authors

P Musto

K C Anderson

M Attal

P G Richardson

A Badros

J Hou

R Comenzo

J Du

B G M Durie

J San Miguel

H Einsele

W M Chen

L Garderet

G Pietrantuono

J Hillengass

R A Kyle

P Moreau

J J Lahuerta

O Landgren

H Ludwig

A Larocca

A Mahindra

M Cavo

A Mazumder

P L McCarthy

A Nouel

S V Rajkumar

A Reiman

E Riva

O Sezer

E Terpos

I Turesson

S Usmani

B M Weiss

A Palumbo

Affiliations

Soon will be listed here.

Citing Articles

Monoclonal Antibodies in Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Current Status and Future Directions.

Ferla V, Farina F, Perini T, Marcatti M, Ciceri F Pharmaceuticals (Basel). 2024; 17(7).

PMID: 39065751 PMC: 11279454. DOI: 10.3390/ph17070901.

Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma.

Geraldes C, Roque A, Sarmento-Ribeiro A, Neves M, Ionita A, Gerivaz R Front Oncol. 2024; 14:1282300.

PMID: 38585008 PMC: 10995327. DOI: 10.3389/fonc.2024.1282300.

Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes.

Escure G, Fournier E, Saade C, Hasan Bou Issa L, Arib I, Tilmont R Haematologica. 2023; 109(4):1289-1292.

PMID: 37855058 PMC: 10985426. DOI: 10.3324/haematol.2023.284050.

Racial differences as predictors of outcomes in young patients with multiple myeloma.

Bao A, Zhao Q, Merritt E, Bumma N, Devarakonda S, Khan A Blood Cancer J. 2022; 12(7):114.

PMID: 35896527 PMC: 9329432. DOI: 10.1038/s41408-022-00708-3.

Boquoi A, Banahan S, Mohring A, Savickaite I, Strapatsas J, Hildebrandt B Ann Hematol. 2022; 101(5):1031-1038.

PMID: 35262868 PMC: 8993729. DOI: 10.1007/s00277-022-04775-1.